A detailed investigation of the performance of an immunometric assay for the quantitation of bone alkaline phosphatase (ALP) in serum showed that precision of this assay was similar to that of lectin precipitation and electrophoretic methods. Relationships for mass and activity measurements of the bone isoform using samples from children and patients with Paget's disease were similar for lectin and electrophoretic methods. Purified liver enzyme showed 100070 cross reactivity in the immunometric assay. However, comparison of the slopes between bone ALP mass and total ALP activity using only samples with predominantly liver or bone isoforms showed that the cross reactivity of the liver isoform in serum was 18'3%. Experiments in which increasing amounts of a sample containing 90% of liver isoform adding to a serum sample from a patient with Paget's disease showed a cross reactivity of 16·5%. The reference range for bone ALP mass was 7-28 /Lg/L for men (n = 77) and 5-20 /Lg/L for women (n = 110) in the age group 20-50 years. In women over 50 years bone ALP was 28% higher. Increased bone ALP mass was also demonstrated in patients with Paget's disease (n = 59), liver disease (n = 95), chronic renal failure (n = 41) and hyperthyroidism (n = 17).
SUMMARY. A detailed investigation of the performance of an immunometric assay for the quantitation of bone alkaline phosphatase (ALP) in serum showed that precision of this assay was similar to that of lectin precipitation and electrophoretic methods. Relationships for mass and activity measurements of the bone isoform using samples from children and patients with Paget's disease were similar for lectin and electrophoretic methods. Purified liver enzyme showed 100070 cross reactivity in the immunometric assay. However, comparison of the slopes between bone ALP mass and total ALP activity using only samples with predominantly liver or bone isoforms showed that the cross reactivity of the liver isoform in serum was 18'3%. Experiments in which increasing amounts of a sample containing 90% of liver isoform adding to a serum sample from a patient with Paget's disease showed a cross reactivity of 16·5%. The reference range for bone ALP mass was 7-28 /Lg/L for men (n = 77) and 5-20 /Lg/L for women (n = 110) in the age group 20-50 years. In women over 50 years bone ALP was 28% higher. Increased bone ALP mass was also demonstrated in patients with Paget's disease (n = 59), liver disease (n = 95), chronic renal failure (n = 41) and hyperthyroidism (n = 17).
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The biochemical markers of bone metabolism can be broadly divided into markers of formation and resorption. 1-3 Serum alkaline phosphatase (ALP) was one of the earliest markers of bone formation following the demonstration of an association between serum enzyme activity and the rate of bone growth in children." However, as the need for more sensitive and specific markers of bone formation became apparent, the limitations of the total enzyme activity measurement were realized.V' This is exemplified in diseases such as chronic renal failure, chronic liver disease, liver disease in childhood and in old age where an elevated serum ALP can arise from more than one source.
The bone isoform of ALP is a member of the tissue non-specific isoenzyme family: it differs from the other members of the family (liver and kidney) in the number of sialic acid and N-acetylglucosamine residues." It is found exclusively in the plasma membrane of the Correspondence: Professor C P Price. osteoblast and is expressed during the maturation and early mineralization phases. R The bone isoform of ALP can be measured by techniques based on heat denaturation," urea or guanidine inactivation.!? lectin precipitation, II electrophoresis with either lectin"-" or neuraminidase pretreatrnent.P or by high performance liquid chromatography.l'v'! However, very few of these methods have been able to provide the desired sensitivity or specificity to detect small changes in the bone isoform which is considered essential for the early detection and management of bone disease. Antibodies (both polyclonal and monoclonal) to the bone isoform have been produced, although in many cases the discrimination between the liver and bone isoforms has not been adequate to meet the clinical need. 16 -19 One immunoassay has been commercialized and some data on its performance has been published.Pv" The primary objective of this study was to assess in detail the performance of this immunometric assay for bone alkaline phosphatase (Tandem" Ostase'?", Hybritech, San Diego, USA) including a more detailed assessment of the specificity of the method, comparison with both lectin and electrophoretic procedures, and establishment of a reference range.
METHODS
Total alkaline phosphatase activity Total catalytic activity was measured in a centrifugal analyser (Monarch, Instrumentation Laboratory, Warrington, UK) at 37°C. Briefly, 3 ILL of serum was mixed with 160 ILL of 4-nitrophenyl phosphate in a 2-amino-2 methyl I-propanol buffer at pH 10·5. The reaction was monitored at 405 nm for a total of 3 min and the activity calculated with reference to the extinction coefficient of the product, 4-nitrophenoL 22 Bone ALP The bone isoform of ALP (bone ALP) was measured using three methods.
lmmunometric assay Serum or calibrator (100 ILL) together with 100 ILL of 125 1 labelled anti-bone ALP (mouse monoclonal antibody) was added to a tube containing a bead coated with a second anti-bone ALP (mouse monoclonal). All tubes were incubated for 19 ± 2 h at 4°C with the tubes partially immersed in a tray of water. The beads were then washed three times with a detergent solution and the total and bound radioactivity counted in an NE 1600 counter (Nuclear Enterprises, Reading, UK). All calibrator and sample measurements were made in duplicate and results were expressed in ILg/L bone ALP. The calibrator was prepared from bone ALP purified from the SAOS-2 human osteosarcoma cell line, and supplied in a liquid form.
Lectin precipitation assay 11
In this assay 100 ILL of serum was mixed with 100 ILL of lectin solution (wheat germ lectiñ 2 giL in acetate buffer 5 mmol/L pH 4· 5, Boehringer Mannheim, West Sussex, UK). After standing for 30 min, the mixture was centrifuged at 10000 g for 2·5 min and the alkaline phosphatase activity of the supernatant measured using the method described earlier. Samples with total activity greater than 800 IU IL were diluted I in 5 with heat inactivated serum prior to lectin pretreatment. The amount of bone ALP present was determined using the calculation lUlL = 1'118 x total ALP -2·35 x activity in supernatant.
Ann Clin Biochem 1995: 32
Electrophoresis with neuraminidase pretreatment 13 In this assay 100 ILL of serum was preincubated with 20 ILL of neuraminidase (2000 U/L) at 20°C for 10 min and 5 ILL of mixture applied to a pre-prepared gel (Isopal Plus, Beckman Instruments, High Wycombe, UK); an aliquot of untreated sample was also run. Current was applied at a constant 150 V for 25 min. The gel was then incubated with freshly prepared buffered substrate for 15 min at 45°C. The gel was then rinsed in water and acetic acid and dried. Quantitation of the isoforms was performed by densitometry (Appraise Densitometer, Beckman Instruments, High Wycombe, UK); the so-called high molecular weight liver isoform was quantitated from densitometry of the untreated sample.
Tissue preparation Liver and intestinal alkaline phosphatase were purified from fresh post mortem tissue using methods described previously.P-" Bone enzyme was also partially purified from a homogenate of an osteoporotic hip.
Subjects
Blood samples were obtained from 248 healthy adult blood donors, 54 elderly women, who were participating in a study of bone mineral density, 94 children attending hospital for diagnosis of conditions not associated with alteration of bone turnover, 59 patients with Paget's disease, 41 patients with chronic renal failure (CRF), 17 hyperthyroid patients and 95 patients with a range of liver diseases.
EXPERIMENTAL PROCEDURES AND RESULTS

Precision
The intra-assay precision was assessed by repeated analysis of pooled sera or control sera (for the immunometric assay only) in a single batch. Different pools were prepared for each of the methods. The interassay precision was assessed by analysing a single aliquot (in duplicate) of the pooled sera or control sera in separate batches. The pooled sera were stored in aliquots at -20°C. The precision of the methods were similar (Table 1) .
Linearity and detection limit
Five patient samples (one from a patient with Paget's disease, two from CRF patients and 
Method comparisons
The distribution of results for bone ALP by the immunometric assay was compared with the total ALP activity and bone ALP activity by lectin and electrophoretic methods in samples from patients with Paget's disease (n =59), liver disease (n = 95) and children with no history of bone disease (n = 67); not all samples were assayed by the lectin and electrophoretic methods (Figs 2-4 ). Results of regression analysis using the Deming procedure" are given in Table 2 .
Comparison between total ALP activity and bone ALP mass is also given in Table 2 . The slopes of the regression lines for children and Paget's patients, after excluding all samples with a total activity above 500 lUlL (to exclude any potential influence from points in one group), were similar (0·264-0·288). The slope of the regression of total ALP and bone ALP mass for samples where the liver isoform constituted 900/0 or more of the total activity (from liver disease 
Method specificity
The specificity of the immunometric assay was assessed in four experiments: group), was compared to the slope with samples in which the bone isoform constituted more than 90llJo of the total activity (from Paget's group), to give an indication of the specificity of the immunometric assay. The proportion of each isoform was determined by the electrophoretic procedure. The specificity determined by this method was 18· 3llJo. (ii) The recovery of bone ALP was assessed by adding a bone extract (containing 115 p.g/L ALP by the immunometric procedure) in a proportion of I : 1 to samples from patients with liver disease (with total ALP activities ranging from 250-600 lUlL and liver ALP greater than 90llJo of the total). The mean recovery of bone ALP was 109· 8llJo (range 87-129, SD 9'7llJo, n= 12 samples). Reference ranges Serum samples from 94 children between the ages of 0 and 20 years and 248 adults were analysed by the immunometric assay. The distribution of results is illustrated in Fig. 6 . Analysis of the distribution by non-parametric statistics indicated a reference range (2' 5 to 97·5 percentile) of 7-28 /Lg/L for males and 5-20 /Lg/L for females up to the age of 50 years.
TARLE 2. Correlation statistics from regression analysis of results obtained for bone alkaline phosphatase (ALP) by the three methods
Clinical samples
The distribution of results obtained using the immunometric assay for the bone isoform in serum from patients with predominantly bone or liver diseases is shown in Fig. 7 . The mean proportion of bone ALP in the sera of patients with Paget's disease, liver disease and children of liver ALP (tissue and biliary components) were as follows: Paget's 13·1 (SO 8· 5; range 4-36%), liver disease 80·3 (SO 13·1; range 50-99%) and children 23'4 (SO 14·8; range 8-62%).
DISCUSSION
The bone and liver isoforms of ALP are coded by the same gene and possess identical amino acid sequences, the differences being in the sialic acid and N-acetylglucosamine residues; however, it is not clear whether the proportion of these residues remain constant throughout the life of the individual, the life of each isoform in the circulation or in different pathological conditions. In addition, the liver isoforms can be found in a second major form linked to phospholipid and membrane fragments in patients with obstructive liver disease. This latter form has been reported to cause problems with the lectin precipitation and electrophoretic methods. Whilst the lectin and electrophoretic methods are known to utilize the chemical differences between the bone and liver isoforms, it is presumed that one of the antibodies employed in the immunometric assays recognizes an epitope encompassing unique carbohydrate residues of the bone isoform. There have been several reports of immunometric assays for bone ALP although few have achieved the desired specificity for the bone isoform. Hill and Wolfert 24 screened a total of 20 441 clones and found 354 positive ones for bone ALP. Of these, one showed less than 3% cross reactivity for the liver isoforms in a competitive assay format.
Our study found similar levels of precision for all three methods. When the immunometric method was compared with the other two methods, the regression slopes for samples from children and patients with Paget's disease (excluding results above 500 lUlL) were similar (in the range O·272-0' 288). There was good agreement between lectin and electrophoretic procedure (the slopes of the regression lines were 0·961 and 0'954 for samples from children and patients with Paget's disease). The agreement for bone ALP for these two methods was poorer in samples from patients with liver disease (slope = O:799).
The apparent 'total' cross reactivity of purified liver ALP in the immunometric procedure made the assessment of method specificity more difficult. Comparison of the slopes between bone ALP and total ALP activity using only samples with either greater than 90% of liver groups were as follows: Paget's 79·5 (SO 12·9; range 56-94070), liver disease 16·5 (SO 11'7; range 0-50), children 76·5 (SO 14'8; range 38-92%). The comparable data for the proportion or bone isoforms indicated a cross reactivity of 18·31170 (ratio of slopes 0·062 :0· 334). This figure is close to that of 16· 5% obtained from the ratio of the slopes obtained in an experiment when liver ALP or bone ALP was added ( Fig. 5 , ratio of slopes 0·0488: O·29). These figures compare favourably with the study of Garnero and Delmas-? who, using the same immunometric assay, found a cross reactivity of 16% for the liver isoform using sera from patients with liver disease. These authors diluted serum samples containing almost entirely liver or bone ALP until the ratio of apparent bone ALP mass (from the immunometric assay) to total ALP activity was constant, indicating the presence of only one isoform. The ratio of the specific activities of the liver and bone samples at that level gave an indication of the cross reactivity. Panigrahi et al., 21 using sera from patients with liver and bone disease, reported a sevenfold preference for the bone isoform which equates to a cross reactivity of 14·3%. These authors used serum samples containing predominantly liver or bone isoforms and compared the 'specific activity' in each group of samples.
The distribution of bone ALP isoforms in an adult reference population indicates a reference range of 7-28 JLg/L for males and 5-20 JLg/L for females up to the age of 50 years. In females, the median values for bone ALP in the 40-50 and 50-60 age groups were 14 and 47% higher than the median value for the 20-40 year age group (P<0·05 and <0·001, respectively). Sorensen," using a lectin precipitation method, demonstrated higher levels of bone ALP in men than women (by about 40%) although he did not generate sufficient data to detect increases in later life. Van Hoof et al. ,26 using an electrophoretic method with neuraminidase pretreatment, found little difference in bone ALP between adult males and females and found no increase with advancing years. Rosalki et al. 27 in a multicentre trial of a lectin precipitation method, found higher levels of bone ALP in males compared to females (approximately 20% higher). However, these authors did not comment on any noticeable increase in the bone ALP in females in advancing years although they studied women up to 77 years of age. Behr and Barnerr" found no difference in the bone ALP levels in normal males and females using lectin precipitation and they did not comment on any trend in values in the older age groups. Schiele et al. ,29 using a heat inactivation technique, did demonstrate a trend for an increase in bone ALP in females over the age of 50 years, related mainly to the menopause with an increase in median value of bone ALP of 30% over the premenopausal mean value. We believe that the clear demonstration of an increase in the bone ALP by the immunometric technique is a strong indication of the potential clinical sensitivity of this method for detection of small increases in the bone ALP. The data on children attending hospital for conditions unrelated to abnormal bone metabolism illustrates the expected distribution in the bone isoform as seen in previous studies, with a peak around the age of [10] [11] [12] [13] [14] [15] years."
The distribution of the bone ALP in patients with Paget's disease, CRF or thyroid disease is consistent with previous observations in the literature. The data in patients with renal failure shows that a small group of CRF patients had low levels of bone ALP. This may reflect reduced bone turnover, as adynamic bone disease is known to be present in some patients with chronic renal disease. The data also provides clear evidence of increases in bone ALP in patients with liver disease, by all three methods.
Although the relative precision of this immunometric assay is comparable to that seen in the lectin precipitation and electrophoretic methods (Table I) , this assay was able to detect subtle changes in the older female reference population that has not been shown with the other methods. This method will therefore enable the earlier detection of changes in bone mineralization than has previously not been possible. More clinical studies are required to determine the true clinical benefit of this method. In the case of patients with obstructive liver disease, the clinical benefit may be limited by the cross reactivity with the liver isoform.
